Darbepoetin in the treatment of the renal anaemia in the patient undergoing peritoneal dialysis previously treated with epoetin alfa;Darbepoetina alfa en el tratamiento de la anemia del paciente en diálisis peritoneal previamente tratado con epoetina alfa

Nefrologia

Volumn 25, Issue 2, 2005, Pages 170-177

  Remón Rodríguez, César ^a,b   Quiros P ^a   Fernandez Marchena D ^a   Hernandez Romero M ^a   Del Castillo, R ^a   Fernandez Ruiz E ^a  

^a HOSPITAL UNIVERSITARIO DE PUERTO REAL   (Spain)

^b NONE   (Spain)

Author keywords

Anaemia; Chronic renal failure; Darbepoetin alfa; Peritoneal dialysis

Indexed keywords

DRUG DERIVATIVE; ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; FEMALE; HUMAN; MALE; MIDDLE AGED; PERITONEAL DIALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS;

EID: 33644825739     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Bergrem H, Danielson BG, Eckardt KU y cols.: A case of antierythropoietin antibodies following recombinat human erythropoietin treatment. En: Bauer C, Koch KM, Scigalla P, Wiezorek L, eds. Erythropoietin. Molecular physiology and clinical applications. Marcel Dekker Inc, New York; pp. 265-273, 1993.
2. Peces R, De la Torre M, Alcázar R y cols.: Antibodies against erythropietin in a patient with erythropoietin resistant anaemia. N Eng J Med 335: 523-524, 1996.
3. Prabhakar DD, Muhlfelder T: Antibodies to recombinant human erythropoietin causing pure red-cell aplasia. Clin Nephrol 47: 331-335, 1997.
4. Casadevall N, Nataf J, Viron B y cols.: Pure red-cell aplasia and antierythropoietin anti-bodies in patients treated with recombinant erythropoietin. N Engl J Med 346: 469-475, 2002.
5. Mercadal L, Sutton L, Casadevall N y cols.: Immunological reaction against erythropoietin causing red-cell aplasia. Nephrol Dial Transplant 17: 943, 2002.
6. Comunicación sobre riesgos de medicamentos para profesionales sanitarios. Agencia Española del Medicamento, 2 de diciembre de 2002.
7. Eckardt KU, Casadevall N: Pure red cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant 18: 865-869, 2003.
8. Krüger A, Schröer W, Röhrs F y cols.: PRCA in a patient with epoetin beta. Nephrol Dial Transplant 18: 1033-1034, 2003.
9. Weber G, Gross J, Kromminga A y cols.: Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol 13: 2381-2383, 2002.
10. Cases A: Darbepoetin alfa: a novel erythropoiesis-stimulating protein. Drugs Today (Barc) 39 (7): 477-495, 2003.
11. Martínez Castelao A, Reyes A, Valdés F y cols. (grupo de estudio NESP 20000114): Estudio multicéntrico de darbeopetin alfa en el tratamiento de la anemia secundaria a insuficiencia renal crónica en dialysis. Nefrología 23(2): 114-124, 2003.
12. Macdougall IC: Novel erythropoiesis stimulating protein. Semin Nephrol 20(4): 375-81, 2000.
13. Egrie JC, Browne JK: Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16 (Supl. 3):3-13, 2001;
14. Molina M, García Hernández A, Navarro MJ, y cols.: Tratamiento de la anemia renal con administración una vez cada dos semanas de darbepoetina alfa en pacientes con insuficiencia renal crónica prediálisis previamente tratados con epoetina alfa. Nefrología 24(1): 54-59, 2004.
15. Locatelli F, Olivares J, Walter R y cols.: Novel erythropoiesis stimulating protein for treatment of anaemia in chronic renal insufficiency. Kidney Int 60(2): 741-747, 2001.
16. Suranyi MG, Lindberg JS, Navarro J y cols.: Treatment of anaemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol 23(2): 106-111, 2003.
17. Locatelli F, Canaud B, Giacardy F y cols.: Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 18(2): 362-369, 2003.
18. Brunkhorst R, Bommer J, Braun J y cols.: Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrol Dial Transplant 19(5): 1224-1230, 2004.
19. IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 37 (Supl.1): S39-S51, 2000.
20. Valderrábano, F: Anaemia management in chronic kidney disease patients: an overview of current clinical practice. Nephrol Dial Transplant 17 (Supl. 1): 13-18, 2002.
21. Eschbach JW, Egrie JC, Downing MR y cols.: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316(2): 73-78, 1987.
22. Evans RW, Arder B, Manninen DL: The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. Jama 263(6): 825-830, 1990.
23. López-Gómez JM: Anemia. En: Manual de Nefrología. Lorenzo V, Torres A, Hernández Marrero D, Ayus JC. Eds. Ediciones Hartcourt, Madrid. pp. 483-491, 2002.
24. Besarab A: Physiological and pharmacodynamic considerations for route of EPO administration. Semin Nephrol 20(4): 364-374, 2000.
25. Jadoul M, Vanrenterghem Y, Foret M y cols.: Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant 19(4): 898-903, 2004.
26. Macdougall IC, Matcham J, Gray SJ (NESP 960245/246 Study Group): Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. Nephrol Dial Transplant 18(3): 576-581, 2003.